Abivax S.A. Q3 2025 earnings summary — revenue, EPS & margin

What went well

The July 2025 public offering landed on the balance sheet: cash and cash equivalents jumped to EUR 589.7 million at September 30, 2025 (from EUR 144.2 million at year-end 2024), driven by EUR 608.1 million of net proceeds, supporting a cash runway into Q4 2027.
Abivax became essentially debt-free during the period, with Heights Capital Management fully converting its notes to equity and the Kreos/Claret structured debt being converted/redeemed (the company notified bondholders on November 28, 2025 of intent to prepay Tranches B and C in full before year-end).
Obefazimod's ABTECT data was showcased at major venues: late-breaking presentations of the 8-week induction results (including updated safety data and prior-advanced-therapy subgroup analyses) at the 2025 United European Gastroenterology (UEG) meeting, plus patient-reported-outcomes data (November 3, 2025) showing significant quality-of-life improvements.
Shareholders' equity swung strongly positive to EUR 511.2 million (from EUR 40.6 million), and total assets reached EUR 652.1 million.

What went wrong

Reported losses ballooned on non-cash items tied to the surging share price: nine-month net loss widened to EUR 254.1 million (from EUR 136.9 million), including a EUR 79.7 million net financial loss.
The financial loss was driven by EUR 36.0 million and EUR 29.9 million fair-value increases on the Heights convertible notes and Kreos/Claret warrants respectively (as the stock rose before conversion), EUR 15.1 million of non-cash royalty-certificate revaluation, and EUR 9.1 million of non-cash FX losses on USD-denominated cash.
Operating loss increased EUR 44.2 million to EUR 174.4 million, with R&D up EUR 25.4 million to EUR 133.4 million (UC Phase 3, Crohn's Phase 2b, other obefazimod studies, and CMC/supply-chain build-out).
G&A rose EUR 16.5 million to EUR 41.8 million, almost entirely from EUR 15.1 million of employer taxes and social contributions on French free-share (AGA) awards triggered by the higher share price - a direct cost of the stock's re-rating.
Operating income declined EUR 4.0 million to EUR 4.1 million year over year.

Guidance Changes

Metric	Period	Current guidance
Cash runway	as of Q3 2025 report	Reaffirmed into the fourth quarter of 2027 (cash of EUR 589.7M at Sep 30, 2025)
ABTECT Phase 3 maintenance topline	upcoming	On track for Q2 2026
Debt	by year-end 2025	Intention to prepay Kreos/Claret Tranches B and C in full before December 31, 2025 (no remaining structured debt)

Metric	YoY	Note
Cash and cash equivalents	EUR 589.7M at Sep 30, 2025	Up EUR 445.5M from year-end 2024 on July 2025 offering net proceeds; partly offset by EUR 137.9M operating use and EUR 23.4M debt service.
R&D costs (9M)	EUR 133.4M (+EUR 25.4M)	UC Phase 3 (+EUR 8.6M), Crohn's Phase 2b (+EUR 5.4M), other obefazimod studies (+EUR 6.0M), CMC/supply chain (+EUR 5.9M).
G&A costs (9M)	EUR 41.8M (+EUR 16.5M)	EUR 15.1M of employer tax/social contributions on AGAs from the higher share price, plus EUR 1.2M higher professional fees.
Operating loss (9M)	EUR 174.4M (+EUR 44.2M)	Higher R&D and G&A.
Net financial loss (9M)	EUR 79.7M (vs EUR 6.7M)	Largely non-cash: fair-value increases on Heights notes and Kreos/Claret warrants, royalty-certificate revaluation and FX.
Net loss (9M)	EUR 254.1M (vs EUR 136.9M)	Wider operating loss plus large non-cash financial charges.

Topic	Previous mention	Current period	Trend
Share-price-driven non-cash charges	-	The stock's re-rating after positive Phase 3 induction data drove large non-cash fair-value and employer-social-charge expenses (Heights EUR 36.0M, Kreos/Claret EUR 29.9M, EUR 15.1M AGA charges), inflating reported losses.	—
Deleveraging	Structured debt outstanding	Heights notes fully converted; Kreos/Claret Tranche A converted and Tranches B/C to be prepaid by year-end 2025.	—
Clinical data dissemination	Topline reported July 2025	Late-breaking UEG presentations plus patient-reported-outcome data reinforced the obefazimod induction profile.	—